SCHEMBL21564484

SCHEMBL21564484

CCOC(=O)/C=C/c1c[nH]c(=O)c(N2CCOCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.41
ALDH1A1 P00352 7/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALOX15 P16050 2/20 0.41
GAA P10253 2/20 0.40
KDM4E B2RXH2 5/20 0.38
MAPT P10636 2/20 0.38
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
PIK3CA P42336 1/20 0.37
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MTOR P42345 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26033873 0.94 MAPT (0.37) AKT1ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL21564468 0.89 MAPT (0.40) ALDH1A1HSD17B10KDM4EMAPTRXFP1
SCHEMBL21564577 0.88 HTR2C (0.40) ALDH1A1KDM4EMAPTRXFP1L3MBTL1
SCHEMBL21553145 0.86 MAPT (0.38) KDM4EMAPTTSHRMAPK1RXFP1
SCHEMBL21564605 0.84 KDM4E (0.39) AKT1HPGDHSD17B10GAAKDM4E
SCHEMBL21564480 0.82 MAPT (0.39) HSD17B10KDM4EMAPTTSHRMAPK1
SCHEMBL6181182 0.76 CA12 (0.46) ALDH1A1GAAKDM4EMAPTMEN1
SCHEMBL6726458 0.76 CA12 (0.46) ALDH1A1GAAKDM4EMAPTMEN1
SCHEMBL20153720 0.75 PIK3CA (0.45) AKT1ALDH1A1HPGDHSD17B10ALOX15
SCHEMBL23258619 0.75 MAPT (0.43) AKT1ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A AKT1 3232/4885ALDH1A1 839/4885HPGD 2047/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A AKT1 3171/4885ALDH1A1 599/4885HPGD 2108/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A AKT1 3232/4885ALDH1A1 839/4885HPGD 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.